Chiesi Farmaceutici S.p.A. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   FOSteR · Incidence of Skin Cancers · Epidermolysis Bullosa…FOSteR · Incidence of Skin Cancers · Epidermolysis Bullosa Receiving Filsuvez

   Enrollment reduced: 580 → 170 participants

   Also in this update: Sponsor changed: Amryt Pharma to Chiesi Farmaceutici S.p.A.; Trial sites expanded: 5 → 12 locations

   Chiesi Farmaceutici S.p.A.·Not specified· NCT06423573· Registry history of NCT06423573 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

2. Notable

   Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed…Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and · Asthma

   Recruitment opened

   Also in this update: Start date changed from estimate of Oct 1, 2026 to Oct 2, 2026

   Chiesi Farmaceutici S.p.A.·Phase 1· NCT07851623· Registry history of NCT07851623 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.